<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HC7505B57716B4E2580A41C6CCC6E2298" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 7166 IH: Make Medicine in America Again Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-03-18</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 7166</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220318">March 18, 2022</action-date><action-desc><sponsor name-id="M001195">Mr. Mooney</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HWM00">Committee on Ways and Means</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Internal Revenue Code of 1986 to provide for extended expensing of pharmaceutical manufacturing property, and for other purposes.</official-title></form><legis-body id="H8F62006E744E417B9A2B1C49C4E86AF6" style="OLC"><section id="HB55262CD285C446A8A73F46706206766" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Make Medicine in America Again Act</short-title></quote>.</text></section><section id="H40008AF8892A4852BB871E3DBCD4BF1F"><enum>2.</enum><header>Extension and expansion of cost expensing provisions for Pharmaceutical Manufacturers</header><subsection id="H1B766CC148B242D4A2F339D007D4E9D5"><enum>(a)</enum><header>Allowance of bonus depreciation for pharmaceutical manufacturing property</header><text display-inline="yes-display-inline"><external-xref legal-doc="usc" parsable-cite="usc/26/168">Section 168(k)(2)(A)</external-xref> of the Internal Revenue Code of 1986 is amended—</text><paragraph id="HA7EC4645917645029CB9A7D272261D0A"><enum>(1)</enum><text>in clause (i), by striking <quote>or</quote> in subclause (III), by striking <quote>or</quote> in subclause (IV), by adding <quote>or</quote> at the end of subclause (V), and by adding at the end the following new subclause: </text><quoted-block style="OLC" id="H3695E02EE25944FFACB2AAA16A62F7EC" display-inline="no-display-inline"><subclause id="H2A877A42CF9D41BA8206F9217CD0CE56"><enum>(VI)</enum><text display-inline="yes-display-inline">which is pharmaceutical manufacturing property (as defined in paragraph 11). </text></subclause><after-quoted-block>, and </after-quoted-block></quoted-block></paragraph><paragraph id="HFA54394B8E184EB08F2748F6F07533C5"><enum>(2)</enum><text>in clause (iii), by striking the period and adding at the end <quote>(other than pharmaceutical manufacturing property).</quote>.</text></paragraph></subsection><subsection id="H214BA92957DA42EB811488D1921528E7"><enum>(b)</enum><header>Application of applicable percentage</header><text>Section 168(k)(6) of such Code is amended by adding at the end the following new subparagraph: </text><quoted-block style="OLC" id="H4A344F2C8B78498280136EB0F0240874" display-inline="no-display-inline"><subparagraph id="H42EF17F6D3DD4F24A156C389FEE21540"><enum>(D)</enum><header>Rule for pharmaceutical manufacturing property</header><text display-inline="yes-display-inline">Notwithstanding any other provisions of this paragraph, in the case of any qualified property which is pharmaceutical manufacturing property, the term <quote>applicable percentage</quote> means, in the case of property placed in service after December 31, 2023, 100 percent. </text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H2805192C08DF4208978EF2F0BFF2FD0B"><enum>(c)</enum><header>Pharmaceutical manufacturing property defined</header><text>Section 168(k) of such Code is amended by adding at the end the following new paragraph: </text><quoted-block style="OLC" id="H48C46850550B498A91DF809E6BEF7E25" display-inline="no-display-inline"><paragraph id="H5BBE322B234745A8832E9F44A3521552"><enum>(11)</enum><header>Pharmaceutical manufacturing property defined</header><text display-inline="yes-display-inline">For purposes of this subsection, the term <quote>pharmaceutical manufacturing property</quote> means property, equipment, buildings, or facilities placed in service in the United States for the purpose of facilitating pharmaceutical manufacturing.</text></paragraph><subsection id="HF1AD5A2CCE064A7CABC50D7B1530F34E"><enum>(a)</enum><header>Effective date</header><text>The amendments made by this section shall apply to property placed in service after December 31, 2022. </text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section><section id="H4F3D8B630C0B4E6DA43336FF99D89027" commented="no" display-inline="no-display-inline" section-type="subsequent-section"><enum>3.</enum><header>Pharmaceutical manufacturing credit</header><subsection id="H056D8CCAE00241769843C2A86F3A223B"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Subpart D of part IV of subchapter A of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/26/1">chapter 1</external-xref> of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:</text><quoted-block id="H5157716C7952492D961A888894012D79" style="OLC"><section id="H46A74808040E4FC3ACCB2CD8F0CA8CB1"><enum>45U.</enum><header>Pharmaceutical manufacturing credit</header><subsection id="HBBA96259DFA84F36BFA1A2A8A682AC7E" commented="no"><enum>(a)</enum><header>In general</header><text>For purposes of section 38, the pharmaceutical manufacturing credit for the taxable year shall be an amount equal to 50 percent of the qualified production activity expenditures of the taxpayer for the taxable year.</text></subsection><subsection id="H937DA2BF97AD4A1D9254FB033358000A" commented="no"><enum>(b)</enum><header>Qualified production activity expenditures</header><text display-inline="yes-display-inline">For purposes of this section—</text><paragraph id="HC04BFB2998804EDC80215A3BAE68EDC7"><enum>(1)</enum><header>In general</header><text>The term <term>qualified production activity expenditures</term> means—</text><subparagraph id="H7F7F1BCA7D9C42B7ACBEAC7CDFAA67F6"><enum>(A)</enum><text display-inline="yes-display-inline">wages paid or incurred to an employee of the taxpayer for services performed by such employee in the conduct of a qualified pharmaceutical manufacturing business in the United States (but only if the employee’s principal place of employment is in the United States), </text></subparagraph><subparagraph id="H3D49648F0AA545DA89F67D0EB5BF9746"><enum>(B)</enum><text display-inline="yes-display-inline">amounts paid or incurred for any tangible personal property (whether or not otherwise properly chargeable to capital account) used in the conduct of a qualified pharmaceutical manufacturing business in the United States (but only if the primary use of such property is in the United States), and</text></subparagraph><subparagraph id="H22357667C14D45238B8B5ABC1C0CE675"><enum>(C)</enum><text>any direct or indirect costs paid or incurred in the conduct of a qualified pharmaceutical manufacturing business in the United States. </text></subparagraph></paragraph><paragraph id="H1A2F8EEE7BC54A0C80ADA0851D8EC4E1"><enum>(2)</enum><header>Qualified pharmaceutical manufacturing business</header><subparagraph id="H5EA56453C10B444F952516D64EDC535C"><enum>(A)</enum><header>In general</header><text>The term <term>qualified pharmaceutical manufacturing business</term> means the trade or business of producing pharmaceuticals and active pharmaceutical ingredients.</text></subparagraph><subparagraph id="H6E116E1F47664FD990659EB9ED6A1782" commented="no"><enum>(B)</enum><header>Active pharmaceutical ingredient</header><text display-inline="yes-display-inline">The term <term>active pharmaceutical ingredients</term> has the meaning given to such term in section 207.1 of title 21, Code of Federal Regulations (and any successor regulations).</text></subparagraph><subparagraph id="HF1532E9B94FD4B059B94F06D67962115" commented="no"><enum>(C)</enum><header>Pharmaceutical</header><text display-inline="yes-display-inline">The term <term>pharmaceutical</term>—</text><clause id="H564C4FA5D3794EFBB7B1CB9C7242D405"><enum>(i)</enum><text>means any drug (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act), and</text></clause><clause id="HF514C61568C944BFA149E61DE145D1E6"><enum>(ii)</enum><text>includes a biological product (as defined in section 351 of the Public Health Service Act).</text></clause></subparagraph></paragraph><paragraph id="HC90C0F7ABF314188A8ACB617032179F1"><enum>(3)</enum><header>Certain health plan expenses treated as wages</header><subparagraph id="HDA5578D5A0A4475DB02BEA8A2F841665"><enum>(A)</enum><header>In general</header><text>For purposes of paragraph (1), the term <term>wages</term> shall include so much of the eligible employer’s qualified health plan expenses as are properly allocable to such wages. </text></subparagraph><subparagraph id="HA2489B3FF72A4DD8931D7D8BEB8EA311"><enum>(B)</enum><header>Qualified health plan expenses</header><text>For purposes of this paragraph, the term <term>qualified health plan expenses</term> means amounts paid or incurred by the eligible employer to provide and maintain a group health plan (as defined in section 5000(b)(1)), but only to the extent that such amounts are excluded from the gross income of employees by reason of section 106(a) of such Code. </text></subparagraph><subparagraph id="HB14FAF3404964359A452FC38FB16A444"><enum>(C)</enum><header>Allocation rules</header><text>For purposes of this paragraph, qualified health plan expenses shall be allocated to qualified wages in such manner as the Secretary may prescribe. Except as otherwise provided by the Secretary, such allocation shall be treated as properly made if made on the basis of being pro rata among employees and pro rata on the basis of periods of coverage (relative to the periods to which such wages relate).</text></subparagraph></paragraph><paragraph id="H0B6E281671F548A6BBE83A5CCB3F958D" commented="no"><enum>(4)</enum><header>United States</header><text>The term <term>United States</term> means the 50 States and the District of Columbia. </text></paragraph></subsection><subsection id="HBB38ED460A844688B55C9F2DA4939A25" commented="no"><enum>(c)</enum><header>Special rules</header><paragraph id="H71332EFA50E746B9B0ABD4411387791D" commented="no"><enum>(1)</enum><header>Reduction in basis</header><text>If a credit is determined under this section with respect to any property by reason of any qualified production activity expenditures described in subsection (b)(1)(B), the basis of such property shall be reduced by the amount of the credit so determined.</text></paragraph><paragraph id="H91D1D194681643239CCA461038194DB6"><enum>(2)</enum><header>Coordination with other credits</header><text>Any qualified production activity expenditures taken into account in determining the amount of the credit under subsection (a) shall not be taken into account in determining a credit under any other provision of this chapter.</text></paragraph><paragraph id="H2003B114B70A44AB894E715EF318AC19" commented="no"><enum>(3)</enum><header>Limitation on wages taken into account</header><text>The amount of wages taken into account under subsection (a) with respect to any employee shall not exceed an amount equal to the contribution and benefit base in effect under section 230 of the Social Security Act for the calendar year in which the taxable year begins.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H01D158C6F07E48E18CC15F841D02FCAA"><enum>(b)</enum><header>Credit allowed against alternative minimum tax</header><text>Section 38(c)(4)(B) of such Code is amended by redesignating clauses (x), (xi), and (xii) as clauses (xi), (xii), and (xiii), respectively, and by inserting after clause (ix) the following new clause:</text><quoted-block style="OLC" id="H0E87563B08354908AA8891FF022554BD" display-inline="no-display-inline"><clause id="H3CC00FE5A85E4C35AB07806AEBB56AC6"><enum>(x)</enum><text display-inline="yes-display-inline">the credit determined under section 45U,</text></clause><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H5569F0C0CF89471382E6005343D363A9"><enum>(c)</enum><header>Denial of deduction</header><text display-inline="yes-display-inline">Section 280C of such Code is amended by adding at the end the following new subsection:</text><quoted-block style="OLC" id="H8A911B44BD7340158A2E0E0309561CC6" display-inline="no-display-inline"><subsection id="HA1A57AC88011411D9A96AE1E980B4BDD"><enum>(i)</enum><header>Pharmaceutical manufacturing credit</header><text display-inline="yes-display-inline">No deduction shall be allowed for that portion of the qualified production activity expenditures (as defined in section 45U(b)) otherwise allowable as a deduction for the taxable year which is equal to the amount of the pharmaceutical manufacturing credit determined for such taxable year under section 45U(a).</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H98851B5B1991447FAE92B6D706890FBA"><enum>(d)</enum><header>Part of general business credit</header><text>Section 38(b) of such Code is amended by striking <quote>plus</quote> at the end of paragraph (32), by striking the period at the end of paragraph (33) and inserting <quote>, plus</quote>, and by adding at the end the following new paragraph:</text><quoted-block style="OLC" id="H9150BDF02143478D828389DCDE327C3D" display-inline="no-display-inline"><paragraph id="HFAFF25AB125C41E2AD06FEB592AA5FDB"><enum>(34)</enum><text display-inline="yes-display-inline">the pharmaceutical manufacturing credit determined under section 45U(a).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H890095C92DA048DC874F6C4ED295EE6F"><enum>(e)</enum><header>Clerical amendment</header><text display-inline="yes-display-inline">The table of sections for subpart D of part IV of subchapter A of chapter 1 is amended by adding at the end the following new item:</text><quoted-block style="OLC" id="H1231A17B12CF4612AAAC7F42EAC6C044" display-inline="no-display-inline"><toc regeneration="no-regeneration"><toc-entry level="section">Sec. 45U. Pharmaceutical manufacturing credit.</toc-entry></toc><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H0090D8C8320C44DAA037B95F7508286A"><enum>(f)</enum><header>Effective date</header><text display-inline="yes-display-inline">The amendments made by this section shall apply to amounts paid or incurred after the date of the enactment of this Act.</text></subsection></section></legis-body></bill> 

